Dr. Hong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3801 Miranda Ave
Palo Alto, CA 94304Phone+1 650-493-5000- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2012- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2007 - 2010
Stanford University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2008 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.Konopleva, M., Dail, M., Daver, N., Garcia, J., Jonas, B., Yee, K., Kelly, K., Vey, N., Assouline, S., Roboz, G., Paolini, S., Pollyea, D., Tafuri, A., Brandwein, J., ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 18
- 25 citationsVenetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A P...> ;Blood. 2023 Mar 16
- RWD-derived response in multiple myeloma.Tao Xu, James Roose, Mellissa Williamson, Ahmed Sawas, Wan-Jen Hong, Huan Jin, Kathleen Maignan, Alberto Rocci, Kasra Yousefi, Shaji Kumar, Stefka Tyanova> ;Plos One. 2023 Jan 1
- Join now to see all
Journal Articles
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
Abstracts/Posters
- A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant AbstractWan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...Wan-Jen Hong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Join now to see all
Press Mentions
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021December 11th, 2021- Two Months After Inking a SPAC Deal, Renovacor Taps New CMO; CureVac Reels in a New Development Chief from Merck KGaAJune 4th, 2021
- Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical OfficerJune 3rd, 2021
Hospital Affiliations
Stanford Health CarePalo Alto, California
VA Palo Alto Heath CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
